Gilead Sciences, Inc. (GILD) vs Novo Nordisk A/S (NVO)
- Gilead Sciences, Inc. GILD 156.19 −0.75%
- Novo Nordisk A/S NVO 38.83 −0.99%
Gilead Sciences, Inc. and Novo Nordisk A/S are both Drug Manufacturers General companies. Gilead Sciences, Inc. is the larger, with a market value of $195.1B against $131.2B — 1.5× the size. Gilead Sciences, Inc. has negative trailing earnings, so its P/E is not meaningful; Novo Nordisk A/S trades at 9.5×. Novo Nordisk A/S grew revenue faster over the last twelve months: 13.2% against 5.52%. Novo Nordisk A/S has the higher net margin (35.5% vs −10.6%) and the higher return on invested capital (28.7% vs −4.48%). Both pay a dividend; Novo Nordisk A/S yields more (4.63% vs 2.08%). Across the 22 metrics below, Novo Nordisk A/S leads on 16 and Gilead Sciences, Inc. on 6.
Valuation
Profitability
| Metric | GILD | NVO | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 79.59% | 80.73% | 72.77% |
| Operating margin | (8.20%) | 43.36% | 18.77% |
| Net margin | (10.64%) | 35.47% | 8.27% |
| Free cash flow margin | 42.50% | 14.79% | 17.18% |
| Return on equity | (20.68%) | 60.84% | 5.87% |
| Return on assets | (6.17%) | 22.00% | 2.57% |
| Return on invested capital | (4.48%) | 28.67% | 6.11% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack